Literature DB >> 3164502

Effect of taurine supplementation on fat and bile acid absorption in patients with cystic fibrosis.

C Colombo1, S Arlati, L Curcio, R Maiavacca, M Garatti, M Ronchi, C Corbetta, A Giunta.   

Abstract

Eleven children with cystic fibrosis (CF) and pancreatic insufficiency were given supplementation with taurine (30-40 mg/kg/day) for 2 months, while taking their usual dosage of enzymatic therapy. One patient dropped out of the study because she developed severe constipation. In the other 10 patients, urinary taurine excretion (88 +/- 30.1 mg/m2s.a./24 h) was similar to that of controls (86.2 +/- 6 mg/m2s.a./24 h) before taurine and increased markedly after supplementation (618.2 +/- 79.97 mg/m2s.a./24 h), indicating efficient intestinal absorption. Their coefficient of fat absorption was 81.2 +/- 2.3% and increased significantly after taurine (91.3 +/- 1.13%; p less than 0.01); the area under the curve of plasma triglyceride postprandial levels (1 +/- 0.1 mg X min/ml) also increased significantly after taurine (1.4 +/- 0.3 mg X min/ml; p less than 0.05), showing values very similar to those of controls. Conversely, no change was observed in the serum postprandial levels of glycocholic acid: the maximum postprandial peak before (1.2 +/- 0.3 mumol/l) and after taurine (1 +/- 0.1 mumol/l) remained significantly lower than in controls (2.4 +/- 0.3 mumol/l); p less than 0.01 and p less than 0.001, respectively. Mean total fecal bile acid (BA) excretion was 10.24 +/- 2.15 mg/kg/day before taurine and 12.8 +/- 4.27 mg/kg/day after taurine (normal pediatric values, 2.91 +/- 1.1 mg/kg/day); however, in the individual patients we found a variable trend, four of them showing a net increase in fecal BA excretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3164502     DOI: 10.3109/00365528809090237

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  6 in total

Review 1.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 2.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

Review 3.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

4.  Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.

Authors:  K H Hsieh; M F Shaio; T N Liao
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

5.  Effect of taurine supplementation on fat and energy absorption in cystic fibrosis.

Authors:  M De Curtis; F Santamaria; P Ercolini; L Vittoria; G De Ritis; V Garofalo; F Ciccimarra
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

6.  A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis.

Authors:  Joaquim Calvo-Lerma; Victoria Fornés-Ferrer; Irene Peinado; Ana Heredia; Carmen Ribes-Koninckx; Ana Andrés
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.